Wedbush initiated coverage on shares of Prevail Therapeutics (NASDAQ:PRVL) in a report released on Monday morning, 24/7 WallStreet reports. The brokerage issued an outperform rating and a $25.00 price target on the stock. Wedbush also issued estimates for Prevail Therapeutics’ Q3 2019 earnings at ($0.55) EPS, Q4 2019 earnings at ($0.60) EPS, Q1 2020 earnings at ($0.59) EPS, Q2 2020 earnings at ($0.61) EPS, Q3 2020 earnings at ($0.63) EPS, Q4 2020 earnings at ($0.64) EPS, FY2020 earnings at ($2.47) EPS, FY2021 earnings at ($2.14) EPS, FY2022 earnings at ($1.99) EPS and FY2023 earnings at ($1.79) EPS.
PRVL has been the subject of a number of other reports. Cowen reaffirmed a buy rating on shares of Avrobio in a research note on Monday. Bank of America set a $68.00 target price on Inphi and gave the company a buy rating in a report on Monday.
PRVL stock opened at $11.59 on Monday. Prevail Therapeutics has a one year low of $9.83 and a one year high of $16.90.
About Prevail Therapeutics
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Featured Story: What is systematic risk?
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.